Moderna (MRNA) Misses Q4 EPS by 18c; offers guidance

Moderna (NASDAQ: MRNA) reported Q4 EPS of ($2.91), $0.18 worse than the analyst estimate of ($2.73). Revenue for the quarter came in at $966 million versus the consensus estimate of $995.44 million.

GUIDANCE:

Moderna sees FY2025 revenue of $1.5-2.5 million, versus the consensus of $2.218 million.

For earnings history and earnings-related data on Moderna (MRNA) click here.

You May Also Be Interested In

• KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
• NCCN adds Natera's Signatera to bladder cancer treatment guidelines
• OneMain (OMF) Reiterated at Market Outperform by Citizens on Updated Estimates